Kyowa Kirin Co., Ltd. (FRA:KY4)

Market Cap	7.97B +9.0%
Revenue (ttm)	2.70B +0.3%
Net Income	364.17M +12.0%
EPS	0.70 +13.3%
Shares Out	n/a
PE Ratio	21.88
Forward PE	n/a
Dividend	0.35 (2.34%)
Ex-Dividend Date	Dec 29, 2025

Volume	n/a
Average Volume	477
Open	15.00
Previous Close	14.60
Day's Range	15.00 - 15.00
52-Week Range	12.30 - 15.50
Beta	n/a
RSI	63.68
Earnings Date	Feb 9, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro...

• Industry: Pharmaceutical Preparations
• Founded: 1949
• Employees: 5,669
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KY4

Financial Performance

In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.

Financial numbers in JPY